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Abstract 
Background: Fruits of Vitis vinifera L., commonly known as grapes, are largely consumed worldwide because of their 
high nutritional and medicinal benefits.
Context and purpose: The present study investigated effects of V. vinifera fruits in ovalbumin-induced animal model 
of bronchial asthma.
Methods: Male wistar rats (except group 1) were sensitized with allergen (ovalbumin, 40 mg/rat + aluminum 
hydroxide, 2 mg/rat). Groups of sensitized animals were treated orally with either vehicle (0.4 mL/kg), standard dexa-
methasone (2.5 mg/kg) or alcoholic extract of V. vinifera dried fruits (31 and 42.5 mg/kg) from day 1 to 28 (n = 6 for 
all groups). Inflammatory markers including cell counts, cytokines such as interleukin (IL)-4, IL-5, IL-1β, tumor necrosis 
factor, immunoglobulin E (IgE), leukotrienes and nitrite levels in both blood/serum and bronchoalveolar fluid were 
analysed. Breathing rate and tidal volume as lung function parameters were examined by spirometer. Lung tissues 
were studied for histamine content and histopathology.
Results: Treatment of sensitized animals with dexamethasone or two doses of V. vinifera fruits extract inhibited 
recruitment of inflammatory cytokines, IgE, nitrites and circulating cells particularly eosinophils in blood/serum and 
bronchoalveolar fluid (p < 0.001, p < 0.01 and p < 0.05). Dexamethasone and V. vinifera fruits extract treatment also 
normalized lung functions and histamine levels compared to ovalbumin-sensitized controls (p < 0.05 and p < 0.01). 
Moreover, both drugs exhibited protection against airway inflammation in lung histology.
Conclusion: Results of study demonstrate the effectiveness of V. vinifera fruits in allergic asthma possibly related to its 
ability to inhibit cellular response and subsequent production of inflammatory cytokines.
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Background
Vitis vinifera (Family: Vitaceae), commonly known as 
grapes, are widely utilized as natural dietary supplements 
due to their unique phytochemical composition and high 
nutritional value. Fruits are a good source of polyphenols 
[1], anthocyanins [2], flavanols [3], stilbenes (resvera-
trol) [4], phenolic acids, proteins, fats, vitamins (C and 
A) [5], minerals (calcium, boron phosphorus) [6], water, 
carbohydrates and fibers [7]. The medicinal value of the 
plant has long been recognized in folklore medicine. 
Documented evidences report anti-diabetic, cytotoxic 
[8], anti-aging [9], cardioprotective [10], hypolipdemic 
[11], anti-inflammatory [12] and antioxidant [13] proper-
ties of seeds and fruits of V. vinifera.
Regarding inflammatory process in chronic airway 
diseases such as asthma and chronic obstructive pulmo-
nary disorder, disease pathology is directly associated 
with increased generation of reactive oxygen species in 
the lungs [14]. Several clinical studies suggest that sup-
plementation of antioxidants benefit adults with mild to 
moderate asthma [15, 16]. Since, oxidative damage plays 
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a significant role in the pathology of bronchial asthma 
therefore this process may represent a potential target of 
the management therapy in asthmatic patients [17].
Asthma is a chronic inflammatory disease of airways 
characterized by reversible constriction of the tracheo-
bronchial tree and airway hyperresponsiveness to vari-
ous stimuli such as environmental allergens, respiratory 
infection, cold air, exercise and some drugs [18, 19]. 
In human beings, allergic asthma is primarily initiated 
by a type I hypersensitivity reaction which represents 
increased susceptibility to produce immunoglobulin E 
(IgE) in response to external allergens, secretion and dif-
ferentiation of which is dependent on CD4+  helper T 
cells (TH2-type) [20, 21]. Activated TH2 cells produce a 
number of cytokines such as interleukin (IL)-3, IL-4, IL-5, 
IL-13 which in turn play role in various process such as 
promoting production of IgE cells by B cells, growth of 
mast cells (IL-4) and survival of eosinophils by IL-5 [22]. 
IL-4 and IL-13 also stimulate epithelial cells to produce 
transforming growth factor alpha (TGF-α) which causes 
mucosal metaplasia and fibroblast proliferation [23]. Pro-
inflammatory mediators including tumor necrosis factor 
(TNF) and granulocyte macrophage colony-stimulating 
factor (GM-CSF) stimulate the expression of vascular 
adhesion molecules on endothelial cells which result in 
an increased influx of inflammatory leukocytes into the 
bronchial tree [24].
With regard to presence of rich plethora of phenolic 
antioxidant constituents such as gallic acid and resvera-
trol in V. vinifera, the present study was conducted to 
examine therapeutic potential of dried fruits of V. vinifera 
in ovalbumin induced rat model of allergic asthma.
Methods
Drugs and chemicals
Ovalbumin (OVA), dexamethasone, gallic acid, hepa-
rin, methacholine, vecuronium bromide were purchased 
from Sigma Aldrich, St. Louis, MO, USA. Standard 
ELISA kits used for the determination of rat interleukin 
(IL)-4, tumor necrosis factor (TNF), IL-1β (Ray Biotech, 
Inc., IL, USA), IgE (Immunology Consultants Laboratory, 
Inc., Portland, OR), IL-5 and leukotrienes LTD4 (Cusabio 
Biotech, Hubei, China), Nitric oxide (NO) calorimetric 
kit (BioVision Research Products, USA) were purchased 
from commercial suppliers. All other chemicals were 
commercial products of analytical reagent grade.
Collection of plant and preparation of extract
Vitis vinifera L. dried fruits were collected from a local 
Indian supplier and botanically authenticated by Dr. 
H. B. Singh at National Institute of Science Commu-
nication and Information Resources, India. A sample 
voucher NISCAIR/RHMD/consult/-2011-12/1752/52) 
was submitted in herbarium of Jamia Hamdard, Ham-
dard University, New Delhi, India, for future reference. 
Dried fruits (1000  g) were homogenized and exhaus-
tively extracted with ethanol for 3 days at 32 ± 2 °C. The 
extract was separated by filtration and concentrated in 
rotary vacuum evaporator (Buchi, USA) and then dried 
in lyophilizer (Uni-step, India, model: PPI –SX72) under 
reduced pressure. The yield obtained was 426.44  g of 
viscous dark brown residue (yield 42.64 % w/w). 250 mg 
extract was dissolved in purified water with the help of 
carboxymethyl cellulose (0.1 %). The prepared suspension 
of alcoholic extract of V. vinifera (VVHE) dried fruits was 
stored in refrigerator till administration to animals.
Quantification of gallic acid by HPTLC
Preparation of sample and standards
10  mg of residue was dissolved in 1  mL of ethanol to 
obtain the concentration of 10  mg/mL. Stock solutions 
of gallic acid were prepared by dissolving 1 mg of gallic 
acid in 1 mL of ethanol and making dilutions to get the 
final concentration, 100 µg/mL of standard. Sample and 
standard solutions were filtered through a 0.22 µM mem-
brane filter.
Chromatographic conditions
For quantifying gallic acid in ethanol extract of V. vinif-
era dried fruits, mobile phase with composition toluene: 
ethyl acetate: formic acid: methanol (3.5:3.5:0.8:0.5) and 
chamber saturation time 35  min was used. The stand-
ard and sample were spotted in the form of bands (width 
8 mm with a CAMAG microliter syringe) on a pre-coated 
silica gel plate  60F-254 aluminum sheets (20  ×  10  cm 
with 0.2  mm thickness; Merck KGaA, Darmstadt, Ger-
many) using a CAMAG Linomat-V applicator (Muttenz, 
Switzerland) attached to CAMAG HPTLC system. The 
plates were pre-washed with methanol and activated at 
105  °C for 5  min prior to chromatography. The stand-
ard and sample-loaded plates were kept in the TLC twin 
trough developing chamber (after saturating with solvent 
vapor for 15  min at 28  ±  2  °C) with respective mobile 
phase till plate run up to 80  mm. The developed plates 
were dried in hot air to evaporate solvents and scanned 
at 292  nm with CAMAG TLC densitometric scanner 3 
operated by WinCATS software, using deuterium lamp. 
To quantify gallic acid 10 µl/spot of sample solution was 
applied on HPTLC plates.
Calibration curves for standards
From the stock solution of standard gallic acid (100 μg/
mL) different volumes 1, 2, 4, 6, 8 and 10 μl, were spot-
ted on a precoated TLC plate to obtain corresponding 
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concentrations of 100, 200, 400, 600 and 800 and 
1000 ng/spot of standard. Each application was done in 
triplicate. The regression equation for gallic acid was y = 
(1216 ±  2.863) +  (6.484 ±  0.007)x; (Co-relation coeffi-
cient, r2 = 0.996 ± 0.0084).
Animals
The guidelines of Government of India regarding con-
trol and supervision of experiments on animals were 
followed. Approval was obtained from the Institutional 
Animal Ethics Committee (IAEC) before conducting the 
present study (Registration no. 173/CPCSEA/748). Male 
wistar rats (180–220  g; 8–10  weeks old) were procured 
from Central Animal House, Jamia Hamdard, New Delhi. 
Animals were housed in polypropylene cages under con-
trolled conditions (room temperature 25 ± 2 °C; humid-
ity 45 ± 5 %; and photoperiod of 12 h light: dark cycle). 
All the animals had free access to standard laboratory 
conditions of diet and water ad  libitum throughout the 
study.
Experimental design
After acclimatization of male wistar rats to the stand-
ard housing conditions, animals were randomly divided 
into 5 groups (6 rats per group). Group 1 (SAL), the non-
sensitized control, received vehicle (0.4 mL/kg); Group 2 
(OVA), the OVA-sensitized or asthma control, was OVA-
sensitized receiving vehicle only; Group 3 (OVA + dex), 
reference standard was OVA-sensitized received dexa-
methasone (2.5 mg/kg, b.w.); Group 4 and 5, the experi-
mental groups (OVA +  VVHE 1 and OVA +  VVHE 2) 
were OVA-sensitized and received alcoholic extract of 
VVHE (31 and 42.5 mg/kg, b.w., respectively). Vitis vin-
ifera fruits are an important constituent of various herbal 
formulations mentioned in Ayurvedic Pharmacopoeia of 
India (API). In view of this, dose of extract was calculated 
from human dose of drug mentioned in API [25]. Drugs 
or vehicle were administered orally from day 1 to 28 once 
daily in the morning hours.
Asthma was induced in rats using the method of 
Abdureyim et  al., with some modifications (2011) [26]. 
All animals (except Group 1) were sensitized with intra-
peritoneal injection of allergen suspension (ovalbumin, 
40  mg/rat  +  aluminum hydroxide, 2  mg/rat) on day 1. 
After 15  days of sensitization, animals were challenged 
by exposure to aerosol consisting of 1  % ovalbumin in 
normal saline for 20 min. Animals in the non-sensitized 
group were exposed to saline following the same pro-
tocol. Exposure to aerosolized solutions were done in a 
closed chamber (dimensions 40 × 32 × 32 cm) once daily 
for 8 consecutive days i.e., from day 15 to day 22, and 
thereafter, on day 25 and day 28.
Lung function and bronchoconstriction test
On day 28, 5 min after OVA exposure, rats were anaes-
thetized with an intraperitoneal injection of sodium 
pentobarbitone (105  mg/kg). Trachea was cannu-
lated using a 12G cannula (2 mm internal diameter) as 
described previously [27]. Cannula was connected to 
a pneumotachograph (spirometer, Model no: FE141, 
ADInstruments, Pty, Australia) with attached flow head 
(Model: MLT 10L, 10 L/min, suitable for rats, ADIn-
struments, Pty, Australia) and differential pressure 
transducer to measure respiratory rate (f, breaths/min). 
Lungs tidal volume (VT, mL/s) were obtained by elec-
tronic integration of airflow signal. Data was stored in 
Power Lab System (ADInstruments, Pty, Australia) and 
acquired through LabChart Programme installed in the 
lab’s computer. Spirometer was calibrated before use to 
record data in terms of L/s and any drift or offsets in sig-
nal due to transducer was nullified to zero for accurate 
measurements. Femoral vein was cannulated with a 24G 
needle cannula filled with heparin for administration 
of methacholine (1.5 mg/kg). Changes in f and VT were 
recorded (1) before and after vehicle administration; (2) 
before and after methacholine treatment. 10–12 res-
piratory cycles were averaged to provide one data point. 
Vecuronium bromide (0.2 mg/kg) was injected intrave-
nously to avoid incidence of spontaneous respiration. 
Excessive bronchial secretions were discharged using a 
small polyethylene tube without disturbing the trachea 
[28].
Bronchoalveolar lavage (BAL) fluid collection
Immediately after measurement of lung function parame-
ters, lungs were lavaged for 3 times with 5 mL (5 mL × 3) 
aliquots of 0.9 % sterile saline solution via cannulated tra-
cheal tube [29]. The BAL fluid recovered from each rat 
was pooled separately (approximately 11–12 mL/rat) and 
centrifuged (1500 rpm, 10 min at 4 °C). Supernatant was 
separated and stored at −80 °C until analysis for IgE and 
cytokines, whereas cell pellet was re-suspended in 1 mL 
of physiological saline for determination of total and dif-
ferential leukocyte count as per method described by 
Jung et al. [30].
Serum preparation and cell count
Following collection of BAL fluid, blood was collected 
by cardiac puncture in two different portions. The first 
aliquot (2.5–3  mL) was collected in a non-heparinized 
tube; centrifuged (3000 rpm, 10 min) and serum stored at 
−80  °C for estimation of IgE and cytokines. The second 
aliquot (0.5 mL) was collected in a heparinized tube and 
stored at 4 °C until determination of total cell and differ-
ential count.
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Within 30  min of collection of heparinized blood, 
total leukocyte count and differential cell count in blood 
was determined by autoanlyser (XP-100, Sysmex Cor-
poration, Japan). Differential cell count was made from 
cytospin smears stained with Leishman’s stain (1.5  % 
in methanol for 6  min). A minimum of 500 cells were 
counted under an optical digital microscope (B1 series 
system, 400× magnification) and classified into eosino-
phils, neutrophils, lymphocytes, macrophages or mono-
cytes using standard morphologic criterion. Absolute 
number of each cell type was calculated.
IgE, LTD4, cytokines, nitric oxide and nitrite levels in serum 
and BAL fluid
The levels of IgE, LTD4 and cytokines (TNF, IL-4, IL-5 
and IL-1β) in serum (500 μl) and BAL fluid (5 mL) were 
measured using enzyme-linked immunosorbent assay 
(ELISA) kits. The samples were analyzed on an auto-
mated ELISA plate reader (Model no. ELX-80MS, Biotek, 
USA). Concentration of total NO and nitrite levels in 
serum and BAL fluid were determined by nitric oxide 
calorimetric kit.
Histamine analysis in lavaged lung tissue
After collection of BAL fluid lung tissue lobes from each 
animal were separately dissected out. One of the lobes 
was homogenized with 2.5  mL normal saline and pro-
cessed for analysis of histamine as per method described 
by Shore et al., using spectrophotometer at 650 nm [30, 
31].
Histological examination
Dissected lung tissues were washed with normal saline 
(NS) and fixed in 10 % neutral formaldehyde solution at 
4 °C for 24 h. The specimens were embedded in paraffin 
wax and sectioned to 5 µm with a rotary microtome. Sec-
tions were stained with 1 % hematoxylin in distilled water 
and 1 % eosin dye in 90 % alcohol (H & E) for studying 
morphology. Tissues were mounted with glycerin jelly 
and cover slipped. The slides were examined under Lab-
con trinocular research microscope and photographs 
were taken with a Nikon Coolpix digital zoom camera 
(model no. S3300).
Ethics aspects
The research was approved by Institutional Animal Eth-
ics Committee (IAEC) before conducting the present 
study under Registration no. 173/CPCSEA/748.
Statistical analysis
Results were reported as mean ± SEM. Statistical analy-
ses were performed using one-way analysis of variance 
(ANOVA) followed by post hoc Tukey’s test. Differ-
ences were considered statistically significant at value of 
p < 0.05. All statistical analyses were performed using the 
Graph Pad software (San Diego, CA, USA).
Results
Quantification of gallic acid by HPTLC in V. vinifera dried 
fruits
The finger print profile of ethanol extract of V. vinif-
era dried fruits in developed solvent system is shown 
in Additional file  1: Figure S1. The ethanolic extract of 
V. vinifera showed 8 peaks where fifth peak at Rf values 
0.43 ± 0.027 with corresponding area of 2943.73 ± 4.542 
coincides with standard gallic acid The mean content of 
gallic acid was calculated to be 2.66  ±  1.12  mg/gm of 
VVHE.
The developed analytical method was optimized by 
applying BBD-RSM (Box-Behnken Design-Response 
Surface Methodology). Analysis of variance for isola-
tion and quantification of gallic acid confirmed that the 
analytical model was statistically significant with F-value 
32.55 and depicted by the value of Prob > F less than 0.05. 
Quadratic equation generated from experimental param-
eters (Additional file  1: Table S1) showed a reasonable 
agreement of predicted R2 (0.8418) with the adjusted R2 
(0.9404) (Additional file  1: Figures S2, S3) given by the 
following equations:
where, A, is amount of toluene (mL); B, is amount of 
ethyl acetate (mL); C, amount of formic acid (mL); and D, 
is time for saturation of developing chamber (min).
Effect of VVHE on lung function parameters
After methacholine injection, respiration rate was sig-
nificantly (p < 0.001) increased in OVA-sensitized control 
group as compared to non-sensitized control group. Ani-
mals receiving VVHE 1 (31 mg/kg) or VVHE 2 (42.5 mg/
kg), exhibited 13 or 21 % decrease (p < 0.05 or p < 0.01) in 
respiratory rate as compared to the OVA-sensitized con-
trol group. There was a considerable reduction in tidal 
volume (p < 0.001) in OVA-sensitized control animals as 
compared to non-sensitized control. Treating asthmatic 
rats with VVHE 2 (42.5 mg/kg, b.w.) markedly increased 
(p < 0.05) tidal volume by 11 % as compared to the OVA-
sensitized control group ( Fig. 1a, b). Similar comparisons 
for dexamethasone treated animals exhibited improve-
ment (p < 0.001) in breathing rate and tidal volume by 37 
and 28 %, respectively.
Y = 2.63+ 0.39A− 0.22B+ 0.1C+ 0.14D− 0.15AB
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Effect of VVHE on circulating cell count in blood
The total number of circulating leukocytes, eosinophils, 
and neutrophils in blood samples of OVA-control rats 
were markedly increased (p  <  0.001) compared to non-
sensitized control animals. In contrast, allergen sensitized 
and challenged rats showed lesser number of lympho-
cytes in blood compared to normal group animals. Ele-
vated number of eosinophils and neutrophils significantly 
reduced after treatment with VVHE 2 (42.5 mg/kg, b.w., 
p  <  0.05) and dexamethasone (p  <  0.01) compared to 
asthma control group. Both drug treatments also normal-
ized the lymphocytes count in blood of animals (Table 1).
Effect of VVHE on inflammatory cellular counts in BAL fluid
The OVA-sensitized control group showed marked 
increase (p < 0.001) in total cells and differential cellular 
count in BAL fluid samples compared to non-sensitized 
control group. Number of eosinophils (p < 0.01), lympho-
cytes (p < 0.01), macrophages (p < 0.01) and neutrophils 
(p < 0.05) reduced significantly in VVHE 2 (42.5 mg/kg, 
b.w.) and dexamethasone (p  <  0.001) treated animals 
compared to OVA-sensitized controls. VVHE at lower 
dose level (31  mg/kg) also reduced these inflammatory 
cells in lavaged fluid but the reduction was statistically 
significant only for lymphocytes and macrophages 
(p < 0.05) (Table 2).
Effect of VVHE on levels of LTD4 and cytokines in serum
Significant (p < 0.001) elevation in serum levels of LTD4 
and all the cytokines, IL-4, IL-5, TNF and IL-1β was 
observed in OVA-sensitized control rats compared to the 
non-sensitized group controls. VVHE 1 (31 mg/kg, b.w.) 
and VVHE 2 (42.5 mg/kg, b.w.) treatment reduced serum 
levels of IL-4 by 17 and 24.2  % (p  <  0.01), IL-5 by 17.1 
and 28.2 % (p < 0.01), TNF by 17 and 30.2 % (p < 0.001), 
IL-1β by 5 and 15.3  % (p  >  0.05 or p  <  0.05) and LTD4 
by 4.3 and 11 % (p > 0.05 or p < 0.05) compared to the 
OVA-sensitized control group (Fig.  2a). However, treat-
ing OVA-sensitized animals with dexamethasone showed 
significant decrease (p < 0.001) in serum levels of LTD4 
by 44.7 % and all the cytokines tested in the study, IL-4 
by 56.6 %, IL-5 by 47.6 %, TNF by 53.3 % and IL-1β by 
57.11 %.
Effect of VVHE on levels of LTD4 and cytokines in BAL fluid
The levels of all the cytokines tested in BAL fluid of 
OVA-control group were significantly high (p  <  0.001) 
compared to non-sensitized group animals. Substantial 
Fig. 1 Effect of VVHE on breathing rate (a) and tidal volume (b) in OVA-sensitized rats. Values shown are mean ± SEM. (n = 6); #p < 0.05, ###p < 0.001 
and ns (non-significant) compared to the non-sensitized control (SAL); **p < 0.01 and ***p < 0.001, compared to the OVA-sensitized control (OVA). 
SAL non-sensitized and vehicle treated control group, OVA OVA-sensitized and vehicle treated control group, OVA + dex OVA-sensitized and dexa-
methasone, 2.5 mg/kg, b.w, treated group, OVA + VVHE 1 OVA-sensitized and VVHE, 31 mg/kg, treated group, OVA + VVHE 2 OVA-sensitized and 
VVHE, 42.5 mg/kg, b.w. treated group
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reduction in levels of cytokines by 30.5  % for IL-4 
(p  <  0.01); 23.2  % for IL-5 (p  <  0.01); 10.6  % for IL-1β 
(p < 0.05); 27.3 % for TNF (p < 0.01) and 12.6 % for LTD4 
(p  <  0.05) was observed in VVHE 2 (42.5  mg/kg, b.w.) 
and dexamethasone (43.5-52.1  %, p  <  0.001) treated 
groups. Treatment with VVHE 1, lower dose of the 
extract (31 mg/kg, b.w.) also attenuated all the cytokines 
and LTD4 levels in BAL fluid but inhibition was statis-
tically significant only for IL-4, IL-5 and TNF (p < 0.05) 
(Fig.  2b). In contrast, animals treated with dexametha-
sone showed significant (p  <  0.001) reduction in BAL 
fluid levels of LTD4 by 44.2  % and all the cytokines 
including IL-4 by 52.1 %, IL-5 by 43.5 %, TNF by 52.04 % 
and IL-1β by 50.5  % compared to OVA-sensitized con-
trol group.
Effect of VVHE on IgE levels of serum and BAL fluid
Allergen sensitization and challenge resulted in sig-
nificant rise (p < 0.001) in IgE levels of both serum and 
BAL fluid samples of rats compared with non-sensitized 
control group. Compared to OVA-control group, animals 
receiving VVHE 1, 31 mg/kg, b.w., or VVHE 2, 42.5 mg/
kg, b.w., exhibited substantial reduction by 17  % or 
31 % in serum (p < 0.01) and 14 % or 26 % in BAL fluid 
(p  <  0.01). Treatment with dexamethasone also caused 
significant (p < 0.001) reduction of IgE levels by 58 % in 
serum and 47.8 % in BAL fluid tested in the study com-
pared to OVA-control group (Fig. 3a, b).
Effect of VVHE on total nitric oxide and nitrite 
concentration
A marked (p  <  0.001) elevation of total NO and nitrite 
levels were observed in OVA-sensitized control animals 
as compared to non-sensitized control group. Com-
pared with the asthmatic group animals receiving VVHE 
2 (42.5 mg/kg, b.w.) showed 29.7 % and 31.4 % reduced 
levels of both nitric oxide and nitrites, respectively, in 
serum and 15 % and 27 % in BAL fluid samples (p < 0.01) 
(Fig. 4). Lower dose of extract (VVHE 1) also decreased 
(p < 0.05) levels of these analytes in both the body fluids. 
Table 1 Effect of VVHE on total cells and differential cell count in blood (×105 cells/ml) of ovalbumin-sensitized rats
Values shown are mean ± S.E.M. (n = 6)
ns (non-significant) compared to OVA-sensitized control (OVA)
SAL non-sensitized and vehicle treated control group, OVA OVA-sensitized and vehicle treated control group, OVA + dex OVA-sensitized and dexamethasone, 2.5 mg/
kg, b.w, treated group, OVA + VVHE 1 OVA-sensitized and VVHE, 31 mg/kg, treated group, OVA + VVHE 2 OVA-sensitized and VVHE, 42.5 mg/kg, b.w. treated group
##  p < 0.01; ### p < 0.001 and NS (non-significant) compared to non-sensitized control (SAL)
* p < 0.05; ** p < 0.01 and *** p < 0.001
Groups Total cells Eosinophils Lymphocytes Macrophages Neutrophils
SAL 9.52 ± 0.46 0.63 ± 0.06 10.85 ± 0.43 6.40 ± 0.65 0.35 ± 0.08
OVA 17.33 ± 1.14### 4.87 ± 0.35### 7.15 ± 0.77## 6.36 ± 0.68ns 4.19 ± 0.46###
OVA + dex 11.50 ± 0.43*** 1.93 ± 0.27** 10.60 ± 0.36* 6.35 ± 0.31ns 1.94 ± 0.26**
OVA + VVHE 1 16.37 ± 0.81ns 4.01 ± 0.47ns 9.93 ± 1.77ns 6.03 ± 0.37ns 1.35 ± 0.36ns
OVA + VVHE 2 13.83 ± 0.76** 2.91 ± 0.42* 10.30 ± 0.43* 6.10 ± 0.40ns 2.42 ± 0.38*
Table 2 Effect of VVHE on total cells and differential cell count in bronchial fluid (×105 cells/ml) of ovalbumin-sensitized 
rats
Values shown are mean ± SEM (n = 6)
ns (non-significant) compared to the OVA-sensitized control (OVA)
SAL non-sensitized and vehicle treated control group, OVA OVA-sensitized and vehicle treated control group, OVA + dex OVA-sensitized and dexamethasone, 2.5 mg/
kg, b.w, treated group, OVA + VVHE 1 OVA-sensitized and VVHE, 31 mg/kg, treated group, OVA + VVHE 2 OVA-sensitized and VVHE, 42.5 mg/kg, b.w. treated group
###  p < 0.001 compared to non-sensitized control (SAL)
* p < 0.05, ** p < 0.01, and *** p < 0.001
Groups Total cells Eosinophils Lymphocytes Macrophages Neutrophils
SAL 7.00 ± 0.52 0.51 ± 0.56 9.92 ± 0.44 5.13 ± 0.52 0.55 ± 0.05
OVA 11.17 ± 0.87### 8.50 ± 0.44### 18.37 ± 0.77### 12.08 ± 0.77### 5.60 ± 0.46###
OVA + dex 4.83 ± 0.48*** 3.07 ± 0.42*** 10.15 ± 0.71*** 6.55 ± 0.81*** 1.16 ± 0.08***
OVA + VVHE 1 8.11 ± 0.45* 7.11 ± 0.31ns 14.15 ± 0.75* 10.02 ± 0.63* 3.27 ± 1.53ns
OVA + VVHE 2 5.83 ± 0.48** 3.85 ± 0.43** 12.32 ± 0.28** 7.76 ± 0.19** 4.01 ± 0.39*
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Treatment with reference drug, dexamethasone reduced 
(p < 0.001) elevated serum levels of total NO by 48.8 % 
and nitrites by 51.5 % and BAL fluids levels by 51 % and 
55.6 %, respectively, compared to OVA-sensitized control 
animals.
Effect of VVHE on histamine levels in lung tissues
Analysis of histamine levels in lung tissues homogenates 
of OVA-control rats were significantly high (p  <  0.001) 
compared to non-sensitized controls. VVHE at both 
dose levels, 31 and 42.5  mg/kg, reduced elevated hista-
mine levels by 25 and 41.6  % (p  <  0.01) compared with 
the OVA-control group (Fig. 5). Whereas treatment with 
standard dexamethasone caused reduction in histamine 
levels of lung tissue homogenates by 66.6 % compared to 
that of OVA-control group (p < 0.001).
Effect of treatments on histopathology of lung tissues
The histological examination of lung tissues from the 
OVA-control group showed reduced bronchiolar lumen, 
infiltration of inflammatory cells into the peribronchial 
tissues and epithelial desquamation. Treatment with 
VVHE and standard reference drug, dexamethasone 
elicited protection against all these pathological features 
as evidenced by the improvement in lumen size and 
reduced cellular infiltration (Fig. 6).
Discussion
Despite all the recent developments, use of herbal drugs 
is increasing as an adjunctive therapy to the conventional 
standard treatments in several chronic diseases such as 
asthma. These health supplements possess a number of 
medicinal properties which need to be investigated by 
adapting a translational approach using modern experi-
mental tools. Ovalbumin-induced rat model of asthma 
is widely used for investigating anti-asthmatic potential 
of drugs in pre-clinical experimental trials [32, 33]. The 
main characteristic feature of this model is bronchial 
hyperresponsiveness to specific stimuli accompanied 
with airway inflammation and constriction.
In our study, ovalbumin sensitization of rats showed 
significant increase in breathing rate followed by reduc-
tion in tidal volume indicating features of broncho-
constriction. Furthermore, all the animals in the asthma 
control group exhibited sneezing, hyperrhinorrhea and 
irritability. Protection against methacholine-induced 
bronchoconstriction in VVHE and dexamethasone 
treated animals demonstrated the bronchodilatory effect 
of the drugs. Amelioration of lung functions after treat-
ment with VVHE may be due to reduced airway inflam-
mation resulting in decrease in lung resistance to air 
flow. Airway hyperresponsiveness with clinical symp-
toms of high breathing rate and reduced tidal volume is 
Fig. 2 Effect of VVHE on cytokine levels in serum (a) and BAL fluid (b) of OVA-sensitized rats. Values shown are mean ± S.E.M. (n = 6); ###p < 0.001 
compared to the non-sensitized control (SAL); *p < 0.05, **p < 0.01, ***p < 0.001, and ns (non-significant) compared to the OVA-sensitized control 
(OVA). SAL non-sensitized and vehicle treated control group, OVA OVA-sensitized and vehicle treated control group, OVA, OVA + dex OVA-sensitized 
and dexamethasone, 2.5 mg/kg, b.w, treated group, OVA + VVHE 1 OVA-sensitized and VVHE, 31 mg/kg, treated group, OVA + VVHE 2 OVA-sensitized 
and VVHE, 42.5 mg/kg, b.w. treated group
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considered as a primary target in the treatment of asthma 
[34].
Allergen-induced airway hyperresponsiveness is 
directly associated with TH2-driven eosniphilic airway 
inflammation [35]. Ovalbumin challenge of sensitized 
rats elicited an increase in number of total cells, eosino-
phils, and neutrophils in both the body fluids (BAL fluid 
and serum) compared to that of non-sensitized control 
group with exception of lymphocyte count in blood. The 
results were consistent with the study of Schster and 
group which explained decrease in lymphocytes num-
ber may be due to migration of these cells from blood 
to bronchial fluid after allergen provocation [36]. Oral 
treatment with VVHE (42.5 mg/kg b.w.) and dexametha-
sone for 28 days significantly reversed the OVA-induced 
infiltration of all the inflammatory cells particularly 
eosinophils, into rat airways, implying the possible role 
of extract in allergen mediated eosniphilic interventions.
TH2 derived inflammatory and pro-inflammatory 
cytokines such as IL-4, IL-5, TNF and IL-1β are extra-
cellular signaling proteins secreted by almost every cell 
under certain conditions. These mediators play a critical 
role in orchestrating all types of inflammatory responses 
in asthmatic airways [37]. Pharmacological therapies 
using specific receptors IL-4, IL-5, TNF and IL-1β block-
ers are likely to constitute a considerable development 
in asthma management [38, 39]. Present study showed 
presence of prominent TH2 type cytokines in OVA-con-
trol group indicating persistent airway inflammation. 
VVHE at both dose levels 31 and 42.5  mg/kg b.w. for 
28 days inhibited elevated levels of IL-4, IL-5, TNF and 
IL-1β in both serum and BAL fluid compared to OVA-
control group. However, changes induced by VVHE 
were less than that observed in corticosteroid dexa-
methasone (2.5  mg/kg oral, for 28  days) treated group 
for inflammation markers in present experiment. Our 
findings with VVHE suggest that the V. vinifera fruits 
could act in asthma via its neutralizing effects on TH2 
derived pro-inflammatory (TNF and IL-1β) and inflam-
matory (IL-4 and IL-5) cytokines, key elements in the 
pathophysiology of bronchial asthma. Cysteinyl leukot-
rienes (cys LT’s), LTB4, LTC4, LTD4, and LTE4, represent 
a heterogeneous group of biologically active mediators 
produced from arachidonic acid. Cys LT’s - D4 and E4 
are stable potent end products which account for clini-
cal features of asthma [40]. VVHE (42.5 mg/kg b.w p.o.) 
elicited substantial inhibitory effects on cytokine LTD4 
in both serum and BAL fluid compared to OVA-control 
animals which may also add to bronchodilation effects of 
the VVHE in the study.
Increased production of immunoglobulin (IgE) in 
allergic asthma (atopy) is the strongest detectable 
Fig. 3 Effect of VVHE on IgE levels in serum (a) and BALF (b) of OVA-sensitized rats. Values shown are mean ± SEM. (n = 6); ###p < 0.001 compared 
to the non-sensitized control (SAL); *p < 0.05, **p < 0.01 and ***p < 0.001, compared to the OVA-sensitized control (OVA). SAL non-sensitized and 
vehicle treated control group, OVA OVA-sensitized and vehicle treated control group, OVA, OVA + dex OVA-sensitized and dexamethasone, 2.5 mg/
kg, b.w, treated group, OVA + VVHE 1 OVA-sensitized and VVHE, 31 mg/kg, treated group, OVA + VVHE 2 OVA-sensitized and VVHE, 42.5 mg/kg, b.w. 
treated group
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predisposing factor in the development of bronchial 
asthma [41]. The anti-inflammatory effects of VVHE in 
asthmatic airways were confirmed in our study while 
evaluating its effect on serum and BAL fluid IgE lev-
els in OVA-sensitized and challenged rats. At both dose 
levels, VVHE (31 and 42.5 mg/kg, p.o.) was found to be 
effective in inhibiting the IgE levels in body fluids tested. 
Marked reduction in levels of both LTD4 and IgE was also 
observed in dexamethasone (2.5 mg/kg oral, for 28 days) 
treated animals.
NO is a gaseous free radical molecule that is formed 
by a wide range of cells, including airway and vascu-
lar smooth muscle cells, endothelial cells, and epithe-
lial cells nerves, activated macrophages. Inflammatory 
cells from asthma patients produce more reactive radi-
cal species including nitrites than those obtained from 
Fig. 4 Effect of VVHE on nitric oxide (NO) and nitrite level in serum and BALF of ovalbumin-sensitized rats. Values shown are mean ± S.E.M. (n = 6); 
###p < 0.001 compared to the non-sensitized control (SAL); *p < 0.05, **p < 0.01 and ***p < 0.001, compared to the OVA-sensitized control (OVA). 
SAL non-sensitized and vehicle treated control group, OVA OVA-sensitized and vehicle treated control group, OVA, OVA + dex OVA-sensitized and 
dexamethasone, 2.5 mg/kg, b.w, treated group, OVA + VVHE 1 OVA-sensitized and VVHE, 31 mg/kg, treated group, OVA + VVHE 2 OVA-sensitized and 
VVHE, 42.5 mg/kg, b.w. treated group
Fig. 5 Effect of treatments on lung tissue histamine levels in ovalbumin-sensitized rats. Values shown are mean ± SEM. (n = 6); ###p < 0.001 com-
pared to the non-sensitized control (SAL); *p < 0.05, **p < 0.01 and ***p < 0.001, compared to the OVA-sensitized control (OVA). SAL non-sensitized 
and vehicle treated control group. OVA OVA-sensitized and vehicle treated control group, OVA, OVA + dex OVA-sensitized and dexamethasone, 
2.5 mg/kg, b.w, treated group, OVA + VVHE 1 OVA-sensitized and VVHE, 31 mg/kg, treated group, OVA + VVHE 2 OVA-sensitized and VVHE, 42.5 mg/
kg, b.w. treated group
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normal subjects [42] which perpetuate the ongoing air-
way inflammation. Some studies report that pH in the 
asthmatic airways falls during acute condition which 
facilitates the conversion of nitrite to NO. Hence, 
increased NO concentrations in the exhaled air of asth-
matic patients may reflect nitrite conversion rather than 
iNOS activity [43, 44]. In the present study while evalu-
ating the effects of VVHE on nitric oxide metabolites in 
serum and BAL fluid of asthmatic rats, VVHE and dexa-
methasone treatments expressed significant suppression 
of both NO and nitrite levels in these body fluids after 
28 days treatment of OVA-sensitized rats. The data sug-
gests that reduced levels of TH2 derived cytokines par-
ticularly IL-4 and IL-5 would had inhibited respective 
secretion of IgE by B cells and infiltration of eosinophils 
and other inflammatory cells into rat airways leading to 
suppression of airway inflammation and radical produc-
tion in lungs.
Polyphenolic compounds present in natural drugs 
have been reported to elicit potent anti-oxidant and 
anti-inflammatory properties mediated through inhibi-
tion of IL-1β, TNF, COX-2 and production of NO2 and 
PGE2 [45–47]. Among them, gallic acid (3, 4, 5-trihy-
droxy benzoic acid) is one of the most important plant 
secondary metabolite present in numerous plants includ-
ing Vitis vinifera L. The phytoconstituent is reported to 
exhibit various biological activities such as antioxidant, 
anti-inflammatory, anti-diabetic, anti-cancer, anti-micro-
bial, anti-aging, cardio-protective, liver fibrosis [48–52]. 
In experimental studies on different models of aller-
gic diseases, gallic acid is demonstrated to suppress of 
allergen induced hypersensitivity reactions in mice and 
inhibit release of histamine and helper T cell subtypes, 
IL-4, IL-5 and IL-2 form human mast cells [49, 53, 54]. 
Accumulating all these data i.e., results of our study on V. 
vinifera fruits and previous findings with gallic acid sug-
gest that amelioration of allergic consequences associated 
with inflammatory processes in asthmatic rats treated 
with VVHE, in the present study, may be attributed to 
the presence of significant amount bioactive constituents 
including gallic acid in V. vinifera fruits.
Conclusion
From the results of the study, we may suggest that VVHE 
might play an important role in the management of bron-
chial asthma by (1) offering protection against ongo-
ing inflammatory process underlying asthma through 
inhibition of histamine release, cytokine production; (2) 
improving lung functioning by counteracting allergen 
induced bronchial hyperresponsiveness; and (3) blocking 
the release of inflammatory cellular infiltration (eosino-
phils, lymphocytes, neutrophils) into airways; Further 
studies may be advised to confirm its use as a valuable 
anti-asthmatic drug in human beings.
Fig. 6 Effect of treatments on the histopathological changes in rat lung tissues. Representative hematoxylin and eosin-stained sections of the rat 
lungs (×10). SAL non-sensitized and vehicle treated control rat showing normal lung histology, OVA OVA-sensitized and vehicle treated control 
rat showing altered bronchiolar lumen and cellular infiltration, OVA, OVA + dex OVA-sensitized and dexamethasone, 2.5 mg/kg, b.w, treated rat, 
OVA + VVHE 1 OVA-sensitized and VVHE, 31 mg/kg, treated rat, OVA + VVHE 2 OVA-sensitized and VVHE, 42.5 mg/kg, b.w. treated rat
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